Melanoma therapy has been revolutionised. Five-year survival after metastatic cancer is a marker for highly likely continuous complete remission (CR), whereas 10-year survival after metastatic cancer is a marker for definitive cure [1,2]. In this respect, modern therapeutic options have proven to lead to a continuous CR, said Prof. Claus Garbe (Eberhard Karls University, Germany) .
In the COMBI-d and COMBI-v trials, first-line treatment with dabrafenib plus trametinib led to long-term benefit in approximately one third of the patients who had unresectable or metastatic melanoma with a BRAF V600E or V600K mutation . More than a decade ago, the diagnosis of metastatic melanoma was still a death knell: long-term survival was non-existent, only 3% of patients survived for 5 years . “The first glimmers of hope were seen i...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Cutaneous adverse events due to EGFR inhibitors Next Article
Statin use elevates risk of eczema and atopic dermatitis »
Table of Contents: WCD 2019
Treating Psoriasis in 2019
Atopic Dermatitis – What is New
Dermal Reactions to Systemic Drugs
Lupus Erythematosus Today
Small Molecules – What to Expect
Optimising the Management of Keloids
Malignant Melanoma – Advances in Management
Best of the Posters
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.